SCHEMBL22455397

SCHEMBL22455397

COc1cc2nccc(N3CCC(NS(=O)(=O)NC(=O)OC(C)(C)C)CC3)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.49
PDGFRB P09619 1/20 0.45
ENPP1 P22413 4/20 0.44
CFTR P13569 2/20 0.44
EHMT2 Q96KQ7 4/20 0.43
EHMT1 Q9H9B1 4/20 0.43
MET P08581 1/20 0.42
KIT P10721 2/20 0.41
PDGFRA P16234 2/20 0.41
FLT3 P36888 1/20 0.40
NSD2 O96028 1/20 0.40
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
KDM4D Q6B0I6 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357281 1.00 NCF1 (0.49) NCF1PDGFRBENPP1CFTREHMT2
SCHEMBL22441543 0.89 NCF1 (0.53) NCF1PDGFRBENPP1EHMT2EHMT1
SCHEMBL22455401 0.88 NCF1 (0.56) NCF1PDGFRBCFTREHMT2EHMT1
SCHEMBL22455038 0.85 ENPP1 (0.62) PDGFRBENPP1PDGFRAMAPK1
SCHEMBL31457633 0.85 NCF1 (0.46) NCF1PDGFRBENPP1CFTREHMT2
SCHEMBL29354609 0.85 EHMT2 (0.49) NCF1PDGFRBENPP1EHMT2EHMT1
SCHEMBL22441446 0.85 NCF1 (0.46) NCF1PDGFRBENPP1CFTREHMT2
SCHEMBL22455394 0.84 NCF1 (0.48) NCF1PDGFRBENPP1CFTREHMT2
SCHEMBL22441525 0.84 ENPP1 (0.44) NCF1PDGFRBENPP1EHMT2EHMT1
SCHEMBL22455359 0.83 ENPP1 (0.44) NCF1PDGFRBENPP1EHMT2EHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407729-B2 Quinoline and quinazoline compounds and methods of use thereof Stingray Therapeutics, Inc. (US) 2022-08-09 US disclosed
CN-113924092-A Quinoline and quinazoline compounds and methods of use thereof 斯汀格瑞治疗股份有限公司 2022-01-11 CN disclosed
US-20200299258-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2020-09-24 US disclosed
WO-2020190912-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Stingray Therapeutics, Inc. (US) 2020-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299258-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ENPP1, ENPP3, PDE7A NCF1 283/4885PDGFRB 3543/4885ENPP1 1/4885
US-11407729-B2 Quinoline and quinazoline compounds and methods of use thereof ENPP1, ENPP3, PDE7A NCF1 283/4885PDGFRB 3543/4885ENPP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.